BioSpace News Archive

Longbio Pharma announced the preliminary phase I data of LP-003 (new generation of anti-IgE antibody) at the 29th Congress of European Rhinologic Society (ERS2023).

Serac Imaging Systems Limited, the medical technology company developing Seracam®, a portable hybrid gamma-optical camera for medical imaging, announces the appointment of James Kaufman as Chief Commercial Officer.

Jumpcode Genomics today announced the results of a study demonstrating the ability to improve genotyping through CRISPR-Cas9-based in vitro repeat depletion, a new method for high-throughput genotyping where repetitive fragments are removed prior to genotyping with low-pass sequencing.

Clarity Pharmaceuticals (ASX: CU6) (“Clarity”) is pleased to announce it has commenced its 64Cu/67Cu SAR-Bombesin Phase I/II trial in metastatic castrate resistant prostate cancer (mCRPC) with the opening of the first site at BAMF Health, Inc in Michigan.

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the submission to the United States Food and Drug Administration (FDA) of a New Drug Application (NDA) for imetelstat for the treatment of transfusion-dependent anemia in adult patients.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced three oral presentations at the Annual Meeting of the European Renal Association (ERA), providing additional support for the efficacy and safety of LUPKYNIS® (voclosporin), a next generation calcineurin inhibitor (CNI) approved in the U.S. and Europe for the treatment of adults with active lupus nephritis (LN).

IIOT-OXYS, Inc. announced it successfully completed a previously disclosed Proof of Concept and signed a Software as a Service contract with a Northeast CNC Component Manufacturer.

Celcuity Inc. is set to join the Russell 2000® and 3000® Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, according to the most recent list of additions posted June 16.

Zynex, Inc today announced that the FDA (Food and Drug Administration) has granted 510(k) market clearance for the company’s CM-1600 blood and fluid volume monitoring device.

BostonGene Highlights Approach to IO Research and Precision Medicine at the 6th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference.